Vaccine News and Research

Latest Vaccine News and Research

New form of pathogen becomes a healthcare challenge in Africa

Research shows how a new, more deadly strain of Salmonella emerged over an 18-month period. Becoming resistant to antibiotics, acquiring the ability to spread from person to person and losing genes along the way, the new strain has become a healthcare challenge in Africa, killing up to one in four patients.

1 Dec 2009

HTDS finalizes contract details with Indian pharmaceutical company

Hard to Treat Diseases' (HTDS; http://www.htdsmedical.com/) operating subsidiary Mellow Hope finalized contract details with one of the largest manufacturer of intravenous medication in India.

1 Dec 2009

Members of priority groups to receive H1N1 vaccines from Department of Health

The Department of Health reminded Pennsylvanians they can begin making appointments today to be vaccinated against the H1N1 flu virus.

1 Dec 2009

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -produced from healthy and tumour cells from the patient him or herself- and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

1 Dec 2009

Phase 1 study of preventive HIV vaccine testing a novel delivery mechanism completed

A Phase 1 study of a preventive HIV vaccine testing a novel delivery mechanism known as electroporation – the use of electrical pulses to increase the immune responses elicited by DNA vaccines – was recently completed in New York City.

1 Dec 2009

Research shows many factors can impact people's decisions on getting vaccinated

Just because a vaccine is available doesn't mean people will choose to be inoculated, according to new UofT research published amid widespread public confusion around the merit of H1N1 flu shots.

1 Dec 2009

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

Tripep completes phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio’s electroporation technology.

30 Nov 2009

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

Novavax, Inc. announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal influenza VLP vaccine to a commercially available trivalent inactivated vaccine, TIV (Fluzone®).

30 Nov 2009

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Bavarian Nordic A/S announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010. If successful, this would be the first marketing approval of IMVAMUNE(R).

30 Nov 2009

Agriflu approved to prevent diseases caused by influenza virus subtypes A and B

The U.S. Food and Drug Administration today approved Agriflu for people ages 18 years and older to prevent disease caused by influenza virus subtypes A and B.

27 Nov 2009

Rights Issue to be carried out by keeping the authorization by the Annual General Meeting, resolves Tripep

The Board of Directors of Tripep AB (publhas on the 27th of November 2009, based on the authorization by the Annual General Meeting resolved to carry out a rights issue.

27 Nov 2009

Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment

All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep’s therapeutic vaccine ChronVac-C have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus.

27 Nov 2009

B cells and their antibodies defend against microbes and control commensal microflora

Microbes populated the earth long before any eukariotic cell. Therefore, in order to survive, mono and multi-cellular organisms had to develop mechanisms of adaptation, cohabitation and defense against bacteria, fungi and viruses. One of these mechanisms is mediated by immunoglobulins in the serum and at mucosal surfaces.

27 Nov 2009

Melvin R. Kaplan to be honored for his lifetime devotion to the care of patients

Melvin R. Kaplan, MD, FACP, a former Board Chair and one of the founders of the research institute that became Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), will be honored by the American College of Physicians for his lifetime devotion to the care of patients.

26 Nov 2009

MUHC's innovative treatment for HIV patients passes first clinical trial successfully

An innovative treatment for HIV patients developed by McGill University Health Centre researchers has passed its first clinical trial with flying colours. The new approach is an immunotherapy customized for each individual patient, and was developed by Dr. J-P. Routy from the Research Institute of the MUHC in collaboration with Dr. R. S-kaly from the Universit- de Montr-al.

26 Nov 2009

Merck, Idera Pharmaceuticals extend their vaccine research collaboration

Idera Pharmaceuticals, Inc. today announced that Merck & Co., Inc., through an affiliate, has extended its research collaboration with Idera for a fourth year. In December 2006, the companies entered into an exclusive license and research collaboration agreement to research, develop, and commercialize vaccine products containing the Company’s investigational agonist compounds targeting Toll-like Receptors (TLRs) 7, 8, and 9 in the fields of oncology, infectious diseases, and Alzheimer’s disease.

26 Nov 2009

Expanded HIV vaccine funding for biotechnology research crucial, says TAI

In honor of World AIDS Day, The AIDS Institute (TAI), one of the nation's leading advocacy organizations for support of people with HIV/AIDS and their providers, joined Nobel Laureate Dr. Francoise Barre-Sinoussi, in calling for government leaders, patient advocates and the research community to expand therapeutic HIV vaccine research.

26 Nov 2009

Lethality of H1N1 virus has dropped from its peak of 3.7, shows new data

Biotech firm Replikins Ltd., which has analyzed the H1N1 virus' genomic data from the 1918 pandemic through the prediction, outbreak, and progress of the current H1N1 pandemic, today issued its latest biochemical analysis of the virus.

25 Nov 2009

WHO investigates cases of H1N1 drug resistance in U.S., Britain

The WHO is looking into reports that patients with "severely suppressed immune systems" in Britain and the U.S. developed resistance Tamiflu, which is used to treat the symptoms of H1N1 (swine flu), a spokesman for the organization said Tuesday, Reuters reports.

25 Nov 2009